Mandatory non-diagnostic biopsies for biomarker research pose risk and inconvenience to cancer patients that should be justified by the knowledge gained. This commentary reflects on the publication by Freeman et. al., which points to a potentially low publication rate of biomarker results from cancer clinical trials requiring non-diagnostic biopsies.
- Received September 26, 2012.
- Accepted October 2, 2012.
- Copyright © 2012, American Association for Cancer Research.